Proceedings of the National Academy of Sciences - PNAS, 2009-09, Vol.106 (38), p.16281-16286
2009
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Highly tumorigenic lung cancer CD133⁺ cells display stem-like features and are spared by cisplatin treatment
- Ist Teil von
- Proceedings of the National Academy of Sciences - PNAS, 2009-09, Vol.106 (38), p.16281-16286
- Ort / Verlag
- United States: National Academy of Sciences
- Erscheinungsjahr
- 2009
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- The identification of lung tumor-initiating cells and associated markers may be useful for optimization of therapeutic approaches and for predictive and prognostic information in lung cancer patients. CD133, a surface glycoprotein linked to organ-specific stem cells, was described as a marker of cancer-initiating cells in different tumor types. Here, we report that a CD133⁺, epithelial-specific antigen-positive (CD133⁺ESA⁺) population is increased in primary nonsmall cell lung cancer (NSCLC) compared with normal lung tissue and has higher tumorigenic potential in SCID mice and expression of genes involved in stemness, adhesion, motility, and drug efflux than the CD133⁻ counterpart. Cisplatin treatment of lung cancer cells in vitro resulted in enrichment of CD133⁺ fraction both after acute cytotoxic exposure and in cells with stable cisplatin-resistant phenotype. Subpopulations of CD133⁺ABCG2⁺ and CD133⁺CXCR4⁺ cells were spared by in vivo cisplatin treatment of lung tumor xenografts established from primary tumors. A tendency toward shorter progression-free survival was observed in CD133⁺ NSCLC patients treated with platinum-containing regimens. Our results indicate that chemoresistant populations with highly tumorigenic and stem-like features are present in lung tumors. The molecular features of these cells may provide the rationale for more specific therapeutic targeting and the definition of predictive factors in clinical management of this lethal disease.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0027-8424eISSN: 1091-6490DOI: 10.1073/pnas.0905653106Titel-ID: cdi_jstor_primary_40485058
- Format
- –
- Schlagworte
- AC133 Antigen, Animals, Antigens, CD - metabolism, Antineoplastic Agents - pharmacology, Antineoplastic Agents - therapeutic use, ATP Binding Cassette Transporter, Sub-Family G, Member 2, ATP-Binding Cassette Transporters - metabolism, Biological Sciences, Biomarkers, Tumor - metabolism, Cancer, Carcinoma, Non-Small-Cell Lung - drug therapy, Carcinoma, Non-Small-Cell Lung - metabolism, Carcinoma, Non-Small-Cell Lung - pathology, Cell growth, Cell Line, Tumor, Cell lines, Cell Survival - drug effects, Chemotherapy, Cisplatin - pharmacology, Cisplatin - therapeutic use, Drug Resistance, Neoplasm, Female, Flow Cytometry, Glycoproteins, Glycoproteins - metabolism, Heterologous transplantation, Humans, Immunohistochemistry, Lung cancer, Lung neoplasms, Lung Neoplasms - drug therapy, Lung Neoplasms - metabolism, Lung Neoplasms - pathology, Lungs, Male, Medical treatment, Mice, Mice, SCID, Middle Aged, Neoplasm Proteins - metabolism, Neoplastic Stem Cells - drug effects, Neoplastic Stem Cells - metabolism, Neoplastic Stem Cells - pathology, Peptides - metabolism, Population growth, Receptors, CXCR4 - metabolism, Stem cells, Survival Analysis, Tumor Burden - drug effects, Tumor Cells, Cultured, Tumors, Xenograft Model Antitumor Assays